Advertisement

Prodrugs pp 217-281 | Cite as

Prodrugs and Parenteral Drug Delivery

  • Jeffery Hemenway
  • Valentino J. Stella
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)

Abstract

Parenteral or injectable drug dosing is the desired route of drug administration under a number of clinical circumstances. In some countries, such as Italy, patients often prefer this route to oral dosing, while in countries like the USA the parenteral drug market is more limited. The most obvious reasons for a parenteral dosage form are when a drug cannot be taken orally due to oral absorption limitations, e.g., insulin for the treatment of diabetes, or when the patient cannot swallow oral medication, e.g., a comatose patient. Additionally, if the drug is orally toxic, as are some anticancer drugs, or immediate action is required, for example, acute life-saving treatment in an emergency room for conditions like a heart attack or an anaphylactic reaction, then injectable dosage forms are essential. For some drugs, a single sustained release intramuscular (IM) injectable dosage resulting in once a month dosing might be desired for patient convenience or for those patients known to be non-compliant.

Keywords

Amino Acid Ester Estramustine Phosphate Betamethasone Sodium Phosphate Etoposide Phosphate Fludarabine Phosphate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abramson FP, and Miller HC. Bioavailability, Distribution and Pharmacokinetics of Diethylstilbestrol Produced from Stilphostrol. J Urol 1982; 128:1336–1339PubMedGoogle Scholar
  2. Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, and Finley R. Taxol: A History of Pharmaceutical Development and Current Pharmaceutical Concerns. J Natl Cancer Inst Monographs 1993; 15:141–147PubMedGoogle Scholar
  3. Albert DH, Conway RG, Magoc TJ, Tapang P, Rhein DA, Luo G, Holms JH, Davidsen SK, Summers JB. Properties of ABT-299, a Prodrug of A-85783, a Highly Potent Platelet-Activating Factor Receptor Antagonist. J Pharmacol Exp Ther 1996a; 277:1595–1606PubMedGoogle Scholar
  4. Albert DH, Magoc TJ, Kleinert HD, Sun E, Reyes AE, Carter GW, Summers JB. Ex Vivo Inhibition of PAF-Induced beta-Thromboglobulin Release in Man by ABT-299, a Potent PAF Antagonist. Adv Exp Med Biol 1996b; 416:381–387PubMedGoogle Scholar
  5. Albert DH, Magoc TJ, Menacherry SD, Morgan DW, Sun E, Reyes AE, Kleinert HD, Carter GW, Summers JB. Ex Vivo Inhibition of β-Thromboglobulin Release Following Administration to Man of ABT-299, A Novel Prodrug of a Potent Platelet Activating Factor Antagonist. Inflamm Res 1997; 46:272–277PubMedGoogle Scholar
  6. Ambrose P. Clinical Pharmacokinetics of Chloramphenicol and Chloramphenicol Succinate. Clin Pharmacokinet 1984; 9:222–238PubMedGoogle Scholar
  7. Anderson B, and Taphouse V. Initial Rate Studies of Hydrolysis and Acyl Migration in Methylprednisolsone 21-Hemisuccinate and 17-Hemisuccinate. J Pharm Sci 1981; 70:181–185PubMedGoogle Scholar
  8. Anderson BD, Conradi RA, and Lambert WJ. Anderson BD, Conradi RA, and Lambert WJ. Carboxyl Group Catalysis of Acyl Transfer Reactions in Corticosteroid 17-and 21-Monoesters J Pharm Sci 1984; 73:604–611PubMedGoogle Scholar
  9. Anderson B, Conradi R, and Kunth K. Strategies in the Design of Solution-Stable, Water-Soluble Prodrugs I: A Physical-Organic Approach to Pro-Moiety Selection for 21-Esters of Corticosteroids. J Pharm Sci 1985a; 74:365–374PubMedGoogle Scholar
  10. Anderson B, Conradi R, Kunth K. and Nail S. Strategies in the Design of Solution-Stable, Water-Soluble Prodrugs II: Properties of Micellar Prodrugs of Methylprednisolone. J Pharm Sci 1985b; 74:375–381PubMedGoogle Scholar
  11. Arikan S, and Rex JH. Ravuconazole (Eisai/Bristol-Myers Squibb). Curr Opin Investig Drugs 2002; 3:555–561PubMedGoogle Scholar
  12. Auzenne E, Donato NJ, Li C, Leroux E, Price RE, Farquhar D, and Klostergaard J. Superior Therapeutic Profile of Poly-L-Glutamic Acid-Paclitaxel Copolymer Compared with Taxol in Xenogeneic Compartmental Models of Human Ovarian Carcinoma. Clin Cancer Res 2002; 8:573–581PubMedGoogle Scholar
  13. Avramis VI, and Plunkett W. Metabolism and Therapeutic Efficacy of 9-,-D-Arabinofuranosyl-2-fluoroadine in Human Leukemic Lymphoblasts. Cancer Res 1982; 42:2587–2591PubMedGoogle Scholar
  14. Avramis VI, Champagne J, Sato J, Krailo M, Ettinger LJ, Poplack DG, Finkelstein J, Reaman G, Hammond GD, and Holcenberg JS. Pharmacology of Fludarabine Phosphate After a Phase I/II Trial by a Loading Bolus and Continuous Infusion in Pediatric Patients. Cancer Res 1990; 50:7226–7231PubMedGoogle Scholar
  15. Barrueco JR, Jacobsen DM, Chang CH, Brockman RW, and Sirotnak FM. Proposed Mechanism of Therapeutic Selectivity of 9-β-D-arabinofuranosyl-2-fluoroadenine Against Murine Leukemia Based Upon Lower Capacities for Transport and Phosphorylation in Proliferative Intestinal Epithelium Compared to Tumor Cells. Cancer Res 1987; 47:700–706PubMedGoogle Scholar
  16. Bebin M, and Bleck TP. New Anticonvulsant Drugs. Focus on Flunarizine, Fosphenytoin, Midazolam and Stiripentol. Drugs 1994; 48:153–171PubMedGoogle Scholar
  17. Bennett SN, McNeil MM, Bland LA, Arduino MJ, Villarino ME, and Perrotta DM. Postoperative Infections Traced to Contamindation of an Intravenous Anesthetic, Propofol. New Engl J Med 1995; 333:147–154PubMedGoogle Scholar
  18. Bentley A, Butters M, Green SP, Learmonth WJ, MacRae JA, Morland MC, O’Connor G, and Skuse J. The Discovery and Process Development of a Commercial Route to a Water Soluble Prodrug, Fosfluconazole. Org Process Res Dev 2002; 6:109–112Google Scholar
  19. Bergenheim AT, and Henriksson R. Pharmacokinetics and Pharmacodynamics of Estramustine Phosphate. Clin Pharmacokinet 1998; 34:163–172PubMedGoogle Scholar
  20. Bhatt R, de Vries P, Tulinsky J, Bellamy G, Baker B, Singer JW, and Klein P. Synthesis and in Vivo Antitumor Activity of Poly(L-glutamic acid) Conjugates of 20(S)-Camptothecin. J Med Chem 2003; 46:190–193PubMedGoogle Scholar
  21. Bleiberg, H. CPT-11 in Gastrointestinal Cancer. Eur J Cancer 1999; 35:371–379PubMedGoogle Scholar
  22. Boucher BA. Fosphenytoin: A Novel Phenytoin Prodrug. Pharmacotherapy 1996; 16:777–791PubMedGoogle Scholar
  23. Boucher BA, Bombassaro AM, Rasmussen SN, Watridge CB, Achari R, and Turlapaty P. Phenytoin Prodrug 3-Phosphoryloxymethyl Phenytoin (ACC-9653): Pharmacokinetics in Patients Following Intravenous and Intramuscular Administration. J Pharm Sci 1989; 78:929–932PubMedGoogle Scholar
  24. Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J, and Von Hoff D. A Phase I Trial of Taxol Given by a 6-Hour Intravenous Infusion. Am J Clin Oncol 1991; 9:1261–1267Google Scholar
  25. Browne TR. Fosphenytoin (Cerebyx). Clin Neuropharmacol 1997; 20:1–12PubMedGoogle Scholar
  26. Browne TR, Kugler AR, and Eldon MA. Pharmacology and Pharmacokinetics of Fosphenytoin. Neurology 1996; 46(6 Suppl 1):S3–7PubMedGoogle Scholar
  27. Bryson HM, Fulton BR, and Faulds D. Propofol: An Update of its Use in Anaesthesia and Conscious Sedation. Drugs 1995; 50:513–559PubMedGoogle Scholar
  28. Bundgaard H, and Jensen E. Allopurinol Prodrugs. Aminomethylbenzoate Esters of Chloramphenicol as a Novel Prodrug Type for Parenteral Administration Int J Pharm 1991; 70:137–146Google Scholar
  29. Bundgaard H, Larsen C, and Thorbek P. Prodrugs as Drug Delivery Systems. XXVI. Preparation and Enzymic Hydrolysis of Various Water-Soluble Amino Acid Esters of Metronidazole. Int J Pharm 1984a; 18:67–77Google Scholar
  30. Bundgaard H, Larsen C, and Arnold E. Prodrugs as Drug Delivery Systems. XXVII. Chemical Stability and Bioavailability of a Water-Soluble Prodrug of Metronidazole for Parenteral Administration. Int J Pharm 1984b; 18:79–87Google Scholar
  31. Bundgaard H, Falch E, Jensen E. A Novel Solution-Stable, Water-Soluble Prodrug Type for Drugs Containing a Hydroxyl or an NH-Acidic Group. J Med Chem 1989; 32:2503–2507PubMedGoogle Scholar
  32. Bundgaard H, Jensen E, Falch E, and Pedersen SB. Allopurinol Prodrugs. V. Water-Soluble N-Substituted (Aminomethyl)benzoyloxymethyl Allopurinol Derivatives for Parenteral or Rectal Delivery. Int J Pharm 1990; 64:75–87Google Scholar
  33. Bundgaard H, Jensen E, and Falch E. Water-Soluble, Solution-Stable, and Biolabile N-Substituted (Aminomethyl)benzoate Ester Prodrugs of Acyclovir. Pharm Res 1991; 8:1087–1093PubMedGoogle Scholar
  34. Burke J, Wargin W, Sherertz R, Sanders K, Blum M, Sarubbi F. Pharmacokinetics of Intravenous Chloramphenicol Sodium Succinate in Adult Patients With Normal Renal and Hepatic Function. J Pharmacokinet Biopharm 1982; 10:601–614PubMedGoogle Scholar
  35. Cheer SM, Goa KL. Parecoxib (parecoxib sodium). Drugs 2001; 61:1133–1141; discussion 1142–1143PubMedGoogle Scholar
  36. Cho MJ, Kurtz RR, Lewis C, Machkovech SM, and Houser DJ. Metronidazole Phosphate-A Water-Soluble Prodrug for Parenteral Solutions of Metronidazole. J Pharm Sci 1982; 71:410–414PubMedGoogle Scholar
  37. Chow MSS. Intravenous Amiodarone: Pharmacology, pharmacokinetics, and clinical use. Ann Pharmacother 1996; 30:637–643PubMedGoogle Scholar
  38. Concilio C, Tezza A, and Perlotto T. Esters of Chloramphenicol. III. Farmaco, Edizione Scientifica 1958; 13:393–398Google Scholar
  39. Creemers GJ, Lund B, and Verweij J. Topoisomerase I Inhibitors: Topotecan and Irenotecan. Cancer Treat Rev 1994; 20:73–96PubMedGoogle Scholar
  40. Daley-Yates PT, Gregory AJ, and Brooks CD. Pharmacokinetic and Pharmacodynamic Assessment of Bioavailability for Two Prodrugs of Methylprednisolone. Br J Clin Pharmacol 1997; 43:593–601PubMedGoogle Scholar
  41. Damen EWP, Wiegerinck PHG, Braamer L, Sperling D, de Vos D, and Scheeren HW. Paclitaxel Esters of Malic Acid as Prodrugs with Improved Water Solubility. Bioorg Med Chem 2000; 8:427–432PubMedGoogle Scholar
  42. Danhauser L, Plunkett W, Liliemark J, Gandhi V, Iacoboni S, and Keating M. Comparison Between the Plasma and Intracellular Pharmacology of 1-β-Darabinofuranosylcytosine and 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate in Patients with Relapsed Leukemia. Leukemia 1987; 1:638–643PubMedGoogle Scholar
  43. Daniels SE, Grossman EH, Kuss ME, Talwalker S, Hubbard RC. A Double-Blind, Randomized Comparison of Intramuscularly and Intravenously Administered Parecoxib Sodium versus Ketorolac and Placebo in a Post-Oral Surgery Pain Model. Clin Ther 2001; 23:1018–1031PubMedGoogle Scholar
  44. Davidsen SK, Summers JB, Albert DH, Holms JH, Heyman HR Magoc TJ, Conway RG, Rhein DA, Carter GW. N-(Acyloxyalkyl)pyridinium Salts as Soluble Prodrugs of a Potent Platelet Activating Factor Antagonist. J Med Chem 1994; 37:4423–4429PubMedGoogle Scholar
  45. DeHaan RM, Metzler CM, Schellenberg D, and Vandenbosch WD. Pharmacokinetic Studies of Clindamycin Phosphate. J Clin Pharm 1973; 190–209Google Scholar
  46. Derendorf H, Moellmann H, Rohdewald P, Rehder J, and Schmidt E. Kinetics of Methylprednisolone and its Hemisuccinate ester. Clin Pharmacol Ther 1985; 37:502–507PubMedCrossRefGoogle Scholar
  47. DeToledo JC, and Ramsay RE. Fosphenytoin and Phenytoin in Patients with Status Epilepticus: Improved tolerability versus increased costs. Drug Safety 2000; 22:459–466PubMedGoogle Scholar
  48. Deutsch HM, Glinski JA, Hernandez M, Haugwitz RD, Narayanan VL, Suffness M, and Zalkow LH. Synthesis of Congeners and Prodrugs. 3. Water-Soluble Prodrugs of Taxol with Potent Antitumor Activity J Med Chem 1989; 32:788–792PubMedGoogle Scholar
  49. Donehower RC, and Rowinsky EK. An Overview of Experience with Taxol (Paclitaxel) in the U.S.A. Cancer Treat Rev 1993; 19Suppl C:63–78PubMedGoogle Scholar
  50. Douros J, and Suffness M. New Antitumor Substances of Natural Origin. Cancer Treat Rev 1981a; 8:63–87PubMedGoogle Scholar
  51. Douros J, and Suffness M. New Natural Products under Development at the National Cancer Institute. Recent Results Cancer Res 1981b; 76:153–175PubMedGoogle Scholar
  52. Earnest MP, Marx JA, and Drury LR. Complications of Intravenous Phenytoin for Acute Treatment of Seizures. Recommendations for Usage. JAMA 1983; 249:762–765PubMedGoogle Scholar
  53. Edmondson HT. Parenteral and Oral Clindamycin Therapy in Surgical Infections: a Preliminary Report. Ann Surg 1973; 178:637–642PubMedGoogle Scholar
  54. Edwards DI. Metronidazole. Antibiotics 1983; 6:121–135Google Scholar
  55. Eng CP, Sehgal SN, Vezina C. Activity of Rapamycin (AY-22,989) against Transplanted Tumors. J Antibiot 1984; 37:1231–1237PubMedGoogle Scholar
  56. Fechner J, Ihmsen H, Hatterscheid D, Schiessl C, Vornov JJ, Burak E, Schwilden H. and Schüttler J. Pharmacokinetics and Clinical Pharmacodynamics of the New Propofol Prodrug GPI 15715 in Volunteers. Anesthesiology 2003; 99:303–313PubMedGoogle Scholar
  57. Feigenbaum JJ, Bergmann F, Richmond SA, Mechoulam R, Nadler V, Kloog Y, and Sokolovsky M. Nonpsychotropic Cannabinoid acts as a Functional N-methyl-Daspartate Receptor Blocker. Proc Natl Acad Sci 1989; 86:9584–9587PubMedGoogle Scholar
  58. Fields SZ, Igwemezie LN, RJ Litam Kaul S, Schacter LP, Schilder PP, Himpler BS, McAleer C, Wright J, and Barbhaiya RH. Phase I Study of Etoposide Phosphate (Etopophos) as a 30-Minute Infusion on Days 1, 3, and 5. Clin Cancer Res 1995; 1:105–111PubMedGoogle Scholar
  59. Fields SZ, Budman DR, Young RR, Kreis W, Ingram R, Schulman P, Cherny RC, Wright J, Behr J, Snow C, and Schacter LP. Phase I Study of High-Dose Etoposide Phosphate in Man. Bone Marrow Transplant 1996; 18:851–856PubMedGoogle Scholar
  60. Fischer JH, Cwik MJ, Luer MS, Sibley CB, and Deyo KL. Stability of Fosphenytoin Sodium with Intravenous Solutions in Glass Bottles, Polyvinyl Chloride Bags, and Polypropylene Syringes. Ann Pharmacother 1997; 31:553–559PubMedGoogle Scholar
  61. Fischer JH, Patel TV, and Fischer PA. Fosphenytoin, Clinical Pharmacokinetics and Comparative Advantages in the Acute Treatment of Seizures. Clin Pharmacokinet 2003; 42:33–58PubMedGoogle Scholar
  62. Flynn GL, and Lamb DJ. Factors Influencing Solvolysis of Corticosteroid-21-Phosphate Esters. J Pharm Sci 1970; 59:1433–1438PubMedGoogle Scholar
  63. Gandhi V, and Plunkett W. Cellular and Clinical Pharmacology of Fludarabine. Clin Pharmacokinet 2002; 41:93–103PubMedGoogle Scholar
  64. Gatti G, Perucca E, Caravaggi M, Poloni M, Frigo GM, and Crema A. Pharmacokinetics of Phenytoin following Intravenous Administration in Epileptic Patients. Farmaco, Edizione Pratica 1977; 32:470–474Google Scholar
  65. Gerber N, Mays DC, Donn KH, Laddu A, Guthrie RM, Turlapaty P, Quon CY, and Rivenburg WK. Safety, Tolerance and Pharmacokinetics of Intravenous Doses of the Phosphate Ester of 3-Hydroxymethyl-5,5-Diphenylhydantoin: a New Prodrug of Phenytoin. J Clin Pharmacol 1988; 28:1023–1032PubMedGoogle Scholar
  66. Glazko A, Carnes H, Kazenko A, Wolf L, and Reutner T. Succinic Acid Esters of Chloramphenicol. Antibiot Annu. 1958:792–802Google Scholar
  67. Godfraind T, Towse G, Van Nueten JM. Cinnarizine-A Selective Calcium Entry Blocker. Drugs Today 1982; 18:27–42Google Scholar
  68. Gray JE, Weaver RN, Moran J, and Feenstra ES. Parenteral Toxicity of Clindamycin 2-phosphate in Laboratory Animals. Toxicol Appl Pharmacol 1974; 27:308–321PubMedGoogle Scholar
  69. Greenwald RB, Pendri A, Bolikal D, and Gilbert CW. Highly Water Soluble Taxol Derivatives: 2′-Polyethylene Glycol Esters as Potential Prodrugs. Bioorg Med Chem Lett 1994; 4:2465–2470Google Scholar
  70. Greenwald RB, Gilbert CW, Pendri A, Conover CD, Xia J, and Martinez A. Drug Delivery Systems: Water Soluble Taxol 2′-Poly(Ethylene Glycol) Ester Prodrugs-Design and In Vivo Effectiveness. J Med Chem 1996; 39:424–431PubMedGoogle Scholar
  71. Greenwald R, Pendri A, Conover C, Lee C, Cho Y, Gillbert C, Martinez A, Wu D, and Hsue M. Camptothecin-20-PEG Ester Transport Forms: The Effect of Spacer Groups on Antitumor Activity. Bioorg Med Chem 1998; 6:551–562PubMedGoogle Scholar
  72. Gunnarsson PO, Andersson SB, and Johansson SA. The Hydrolysis of Estramustine Phosphate; In Vitro Studies. Eur J Drug Metab Pharmacokinet 1983; 8:395–402PubMedCrossRefGoogle Scholar
  73. Haisma HJ, Boven E, van Mujien M. de Jong J, van der Vijgh WJ, and Pinedo HM. A Monoclonal Antibody-Beta-Glucuronidase Conjugate as Activator of the Prodrug Epirubicin-Glucuronide for Specific Treatment of Cancer. Br J Cancer 1992; 66:474–478PubMedGoogle Scholar
  74. Haisma HJ, van Muijen M. Pinedo HM, and Boven E. Comparison of Two Anthracycline-Based Prodrugs for Activation by Monoclonal Antibody-Beta-Glucuronidase Conjugate In the Specific Treatment of Cancer. Cell Biophys. 1994; 24:185–192PubMedGoogle Scholar
  75. Hanessian S. N6-(Dimethylamino)methylene Derivative of 9-β-D-Arabinofuranosyladenine as an Antiviral Agent. J Med Chem 1973; 16:290–292PubMedGoogle Scholar
  76. Hanson BA. Evaluation of a Phosphoryloxymethyl (POM) Prodrug of Camptothecin: Preformulation, Formulation and Pharmacokinetic Studies. Ph.D. Dissertation University of Kansas 2002:181pGoogle Scholar
  77. Hanson BA, Schowen RL, and Stella VJ. A Mechanistic and Kinetic Study of the E-ring Hydrolysis and Lactonization of a Novel Phosphoryloxymethyl Prodrug of Camptothecin. Pharm Res 2003; 20:1031–1038PubMedGoogle Scholar
  78. Hayashi R, Kitamoto N, Iizawa Y, Ichikawa T, Itoh K, Kitazaki T, and Okonogi K. Efficacy of TAK-457, a Novel Intravenous Triazole, against Invasive Pulmonary Aspergillosis in Neutropenic Mice. Antimicrob Agents Chemother 2002; 46:283–287PubMedGoogle Scholar
  79. Hayashi Y, Skwarczynski M, Hamada Y, Sohma Y, Kimura T, and Kiso Y. A Novel Approach of Water-Soluble Paclitaxel Prodrug with No Auxiliary and No Byproduct: Design and Synthesis of Isotaxel. J Med Chem 2003; 46:3782–3784PubMedGoogle Scholar
  80. Heel RC, Brogden RN, Speight TM, Avery GS. Loxapine: a review of its Pharmacological Properties and Therapeutic Efficacy as an Antipsychotic Agent. Drugs 1978; 15:198–217PubMedGoogle Scholar
  81. Herbranson DE, Speicher ER, and Rosenberg LS. Stable Pharmaceutical Compositions of 3-(Hydroxymethyl)-5,5-Diphenylhydantoin Disodium Phosphate Ester. US patent 4,925,860, May 15, 1990Google Scholar
  82. Hersh MR, Kuhn JG, Phillips JL, Clark G, Ludden TM, and Von Hoff DD. Pharmacokinetic Study of Fludarabine Phosphate (NSC 312887). Cancer Chemother Pharmacol 1986; 17:277–280PubMedGoogle Scholar
  83. Hiddemann W, and Pott-Hoeck C. Fludarabine in the Management of Malignant Lymphomas. Drugs 1994; 47Suppl 6:50–66PubMedCrossRefGoogle Scholar
  84. Hong W-H, and Szulczewski DH. Stability of Vidarabine-5?-Phosphate in Aqueous Solution. J Parenteral Sci Technol 1984; 38:60–64Google Scholar
  85. Hudes G, Haas N, Yeslow G, Gillon T, Gunnarsson PO, Ellman M, Nordle O, Eriksson, B, Miller L, Cisar L, Kopreski M, Viaro D, and Hartley-Asp B. Phase I Clinical and Pharmacologic Trial of Intravenous Estramustine Phosphate. J Clin Oncol 2002; 20:1115–1127PubMedGoogle Scholar
  86. Ichikawa T, Kitazaki T, Matsushita Y, Yamada M, Hayashi R, Yamaguchi M, Kiyota Y, Okonogi K, and Itoh K. Optically Active Antifungal Azoles. XII. Synthesis and Antifungal Activity of the Water-soluble Prodrugs of 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone. Chem Pharm Bull 2001; 49:1102–1109PubMedGoogle Scholar
  87. Ishikawa T, Nakayama Y, Tomimoto M, Niwa SI, Kamiyama K, Hashiguchi S, Iizawa Y, Okonogi K, and Miyake A. Studies on Anti-MRSA Parenteral Cephalosporins: IV. A Novel Water-Soluble N-Phosphono Type Prodrug for Parenteral Administration. J Antibiot 2001; 54:364–374PubMedGoogle Scholar
  88. Ishikawa T, Matsunaga N, Tawada H, Kuroda N, Nakayama Y, Ishibashi Y, Tomimoto M, Ikeda Y, Tagawa Y, Iizawa Y, Okonogi K, Hashiguchi S, and Miyake A. TAK-599, A Novel N-Phosphono Type Prodrug of Anti-MRSA Cephalosporin T-91825: Synthesis, Physicochemical and Pharmacological Properties. Bioorg Med Chem 2003; 11:2427–2437PubMedGoogle Scholar
  89. Jain KK. Evaluation of Intravenous Parecoxib for the Relief of Acute Postsurgical Pain. Expert Opin Investig Drugs 2000; 9:2717–2723PubMedGoogle Scholar
  90. Jamerson BD, Donn KH, Dukes GE, Messenheimer JA, Brouwer KL, and Powell JR. Absolute Bioavailability of Phenytoin After 3-Phosphoryloxymethyl Phenytoin Disodium (ACC-9653) Administration to Humans. Epilepsia 1990; 31:592–597PubMedGoogle Scholar
  91. Jensen E, and Bundgaard H. N-substituted (aminomethyl)benzoate 21-esters of Corticosteroids as Water-soluble, Solution-stable and Biolabile Prodrugs. Acta Pharm Nord 1992; 4:35–42PubMedGoogle Scholar
  92. Jensen E, Bundgaard H, Falch E. Design of a water-soluble, solution-stable and biolabile prodrug of metronidazole for parenteral administration: N-substituted aminomethylbenzoate esters. Int J Pharm 1990; 58:143–53Google Scholar
  93. Johnson K, Amidon G, and Pogany S. Solution Kinetics of a Water-soluble Hydrocortisone Prodrug: Hydrocortisone-21-lysinate. J Pharm Sci 1985; 74:87–89PubMedGoogle Scholar
  94. Karim A, Laurent A, Slater ME, Kuss ME, Qian J, Crosby-Sessoms SL, and Hubbard RC. A Pharmacokinetic Study of Intramuscular (i..m.) Parecoxib Sodium in Normal Subjects. J Clin Pharmacol 2001; 41:1111–1119PubMedGoogle Scholar
  95. Kauffman R, Thirumoorthi M, Buckley J, Aravind M, and Dajani A. Pharmacokinetics of Chloramphenicol and Chloramphenicol Succinate in Infants and Children. J Pediatr 1981; 99:963–967PubMedGoogle Scholar
  96. Kawamura M, Yamamoto R, and Fujisawa S. Pharmaceutical Studies on Water-Soluble Corticosteroid Derivatives. II. Stability of Hydrocortisone 21-Aminoalkylcarboxylates in Solution. Yakugaku Zasshi 1971a; 91:863–870PubMedGoogle Scholar
  97. Kawamura M, Yamamoto R, and Fujisawa S. Pharmaceutical Studies on Water-Soluble Corticosteroid Derivatives. III. Stability of Hydrocortisone 21-Sulfobenzoates and 21-Sulfate in Solution. Yakugaku Zasshi 1971b; 91:871–878PubMedGoogle Scholar
  98. Kawamura M, Yamamoto R, and Fujisawa S. Pharmaceutical Studies on Water-Soluble Corticosteroid Derivatives. IV. Stability of Prednisolone 21-Esters in Solution. Yakugaku Zasshi 1971c; 91:879–884PubMedGoogle Scholar
  99. Keating MJ. Fludarabine Phosphate in the Treatment of Chronic Lymphocytic Leukemia. Semin Oncol 1990; 17(5 Suppl 8):49–62PubMedGoogle Scholar
  100. Kelly WK, Zhu, AX, Scher H, Curley T, Fallon M, Slovin S, Schwartz L, Larson S, Tong W, Hartley-Asp B, Pellizzoni C, and Rocchetti M. Dose Escalation Study of Intravenous Estramustine Phosphate in Combination with Paclitaxel and Carboplatin in Patients with Advanced Prostate Cancer. Clin Cancer Res 2003; 9:2098–2107PubMedGoogle Scholar
  101. Kreienbaum M. Stability of Betamethasone Sodium Phosphate, Hydrocortisone Sodium Phosphate, and Prednisolone Sodium Phosphate Injections Submitted by U.S. Hospitals. Am J Hosp Pharm 1986; 43:1747–1750PubMedGoogle Scholar
  102. Kreis W, Budman DR, Vinciguerra V, Hock K, Baer J, Ingram R, Schacter LP, and Fields SZ. Pharmacokinetic Evaluation of High-Dose Etoposide Phosphate After a 2-Hour Infusion in Patients with Solid Tumors. Cancer Chemother Pharmacol 1996; 38:378–384PubMedGoogle Scholar
  103. Krise JP, Zygmunt J, Georg GI, Stella VJ. Novel Prodrug Approach for Tertiary Amines: Synthesis and Preliminary Evaluation of N-Phosphonooxymethyl Prodrugs. J Med Chem 1999a; 42:3094–3100PubMedGoogle Scholar
  104. Krise JP, Narisawa S, Stella VJ. A Novel Prodrug Approach for Tertiary Amines. 2. Physicochemical and in Vitro Enzymatic Evaluation of Selected NPhosphonooxymethyl Prodrugs. J Pharm Sci 1999b; 88:922–927PubMedGoogle Scholar
  105. Krise JP, Charman WN, Charman SA, Stella VJ. A Novel Prodrug Approach for Tertiary Amines. 3. In Vivo Evaluation of Two N-Phosphonooxymethyl Prodrugs in Rats and Dogs. J Pharm Sci 1999c; 88:928–932PubMedGoogle Scholar
  106. Laboratoires Francais de Chimiotherapie. Sodium 21-hemisuccinate of 9α-Fluoro-16α-methyl-3,20-dioxo-11ß,17α,21-trihydroxy-1,4-pregnadiene. French Patent FR M 186, March 20, 1961:3 pGoogle Scholar
  107. Larsen C, Kurtzhals P, and Johansen M. Kinetics of Regeneration of Metronidazole from Hemiesters of Maleic Acid, Succinic Acid and Glutaric Acid in Aqueous Buffer, Human Plasma and Pig Liver Homogenate. Int J Pharm 1988; 41:121–129Google Scholar
  108. Laubach GD, P’an SY, Rudel HW. Steroid Anesthetic Agent. Science 1955; 122:78PubMedGoogle Scholar
  109. Lederer V. Betamethasone Sodium Phosphate Injection: High-Dose Regimen in Septic Shock. Clin Ther 1984; 6:719–26PubMedGoogle Scholar
  110. LePage GA, and Hersh EM. Cyclic Nucleotide Analogs as Carcinostatic Agents. Biochem Biophys Res Commun 1972; 46:1918–1922PubMedGoogle Scholar
  111. Leppik IE, Boucher BA, Wilder BJ, Murthy VS, Watridge C, Graves NM, Rangel RJ, Rask CA, and Turlapaty P. Pharmacokinetics and Safety of a Phenytoin Prodrug Given I.V. or I.M. in Patients. Neurology 1990; 40:456–460PubMedGoogle Scholar
  112. Leu, Y-L, Roffler SR, and Chern J-W. Design and Synthesis of Water-Soluble Glucuronide Derivatives of Camptothecin for Cancer Prodrug Monotherapy and Antibody-Directed Enzyme Prodrug Therapy (ADEPT). J Med Chem 1999; 42:3623–3628PubMedGoogle Scholar
  113. Li C, Yu D-F, Newman RA, Cabral F, Stephens, LC, Hunter N, Milas L, and Wallace S. Complete regression of Well-Established Tumors Using a Novel Water-Soluble Poly(L-Glutamic Acid)-Paclitaxel Conjugate. Cancer Res 1998; 58:2404–2409PubMedGoogle Scholar
  114. Liu X, Lynn BC, Zhang J, Song L, Bom D, Du W, Curran DP, and Burke TG. A Versatile Prodrug Approach for Liposomal Core-Loading of Water-Insoluble Camptothecin Anticancer Drugs. J Am Chem Soc 2002; 124:7650–7651PubMedGoogle Scholar
  115. Luer MS. Fosphenytoin. Neurol Res 1998; 20:178–182PubMedGoogle Scholar
  116. Maeda H. The Enhanced Permeability and Rentention (EPR) Effect in Turmor Vasculature: The Key Role of Tumour-Selective Macromolecular Drug Targeting. Adv Enzyme Regul 2001; 41:189–207PubMedGoogle Scholar
  117. Maeda H, Wu J, Swana Y, Matsumura Y, and Hori K. Tumour Vascular Permeability and the EPR effect in Macromolecular Therapeutics: A Review. J Control Release 2000; 65:271–284PubMedGoogle Scholar
  118. Malspeis L, Grever MR, Staubus AE, and Young D. Pharmacokinetics of 2-F-ara-A (9-β-D-arabinofuranosyl-2-fluoroadenine) in Cancer Patients During the Phase I Clinical Investigation of Fludarabine Phosphate. Semin Oncol 1990; 17(5 Suppl 8):18–32PubMedGoogle Scholar
  119. Mamber SW, Mikkilineni AB, Pack EJ, Rosser MP, Wong H, Ueda Y, and Forenza S. Tubulin Polymerization by Paclitaxel (Taxol) Phosphate Prodrugs After Metabolic Activation with Alkaline Phosphatase. J Pharmacol Exp Ther 1995; 274:877–883PubMedGoogle Scholar
  120. Martel RR, Klicius, J, Galet S. Inhibition of the Immune Response by Rapamycin, A New Antifungal Antibiotic. Can J Physiol Pharmacol 1977; 55:48–51PubMedGoogle Scholar
  121. Mathew AE, Mejillano MR, Nath JP, Himes RH, and Stella VJ. Synthesis and Evaluation of Some Water-Soluble Prodrugs and Derivatives of Taxol with Antitumor Activity. J Med Chem 1992; 35:145–151PubMedGoogle Scholar
  122. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, and Sparreboom A. Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11). Clin Cancer Res 2001; 7:2182–2194PubMedGoogle Scholar
  123. Mathijssen RH, Loos WJ, Verweij J, and Sparreboom A. Pharmacology of Topisomerase I Inhibitors Irinotecan (CPT-11) and Topotecan. Curr Cancer Drug Targets 2002; 2:103–123PubMedGoogle Scholar
  124. Mechoulam R, Lander N, Breuer A, and Zahalka J. Synthesis of the individual, pharmaco-logically distinct enantiomers of a tetrahydrocannabinol derivative. Tetrahedron: Asymmetry 1990; 1:315–318Google Scholar
  125. Melby J, and Cyr M. Comparative studies on absorption and metabolic disposal of water-soluble corticosteroid esters. Metabolism 1961; 10:75–82PubMedGoogle Scholar
  126. Menuck M, and Voineskos G. Rapid Parenteral Treatment of Acute Psychosis. Compr Psychiatry 1981; 22:351–61PubMedGoogle Scholar
  127. Mi Z, and Burke TG. Differential Interactions of Camptothecin Lactone and Carboxylate Forms with Human Blood Components. Biochem 1994; 33:10325–10336Google Scholar
  128. Mollmann H, Rohdewald P, Barth J, Mollmann C, Verho M, and Derendorf H. Comparative Pharmacokinetics of Methylprednisolone Phosphate and Hemisuccinate in High Doses. Pharm Res 1988; 5:509–513PubMedGoogle Scholar
  129. Montgomery JA, and Hewson K. Nucleosides of 2-Fluoroadenine. J Med Chem 1969; 12:498–504PubMedGoogle Scholar
  130. Montgomery JA, and Shortnacy AT. Prodrug Derivatives of 9-β-D-arabinofuranosyl-2-fluoroadenine. US Patent 4,357,324, November 2, 1982; 14pGoogle Scholar
  131. Moosavi-Movahedi AA, Hakimelahi S, Chamani J, Khodarahmi GA, Hassanzadeh F, Luo FT, Ly TW, Shia KS, Yen CF, Jain ML, Kulatheeswaran R, Xue C, Pasdar M, and Hakimelahi GH. Design, Synthesis, and Anticancer Activity of Phosphonic Acid Diphosphate Derivative of Adenine-Containing Butenolide and its Water-Soluble Derivatives of Paclitaxel with High Antitumor Activity. Bioorg Med Chem 2003; 11:4303–4313PubMedGoogle Scholar
  132. Morita K, Noguchi S, and Nishikawa M. Takeda Chemical Industries, Ltd. Steroid Dialkylamino Acetates. Japanese patent, JP 38023174; 1963. 3 pGoogle Scholar
  133. Mosher HS, Reinhart J, and Prosser HC. The Phosphorylation of Chloromycetin. J Am Chem Soc 1953; 75:4899–4901Google Scholar
  134. Mueller C, and Wollmann H. Stability of Drugs and Pharmaceuticals. 26. Studies on the Stability of Drugs with Medium Stability. Pharmazie 1986; 41:53Google Scholar
  135. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, and Selawry OS. Phase I Clinical Trial of Weekly and Daily Treatment with Camptothecin (NSC-100880): Correlation with Preclinical Studies. Cancer Chemother Rep 1972; 56:515–521PubMedGoogle Scholar
  136. Murdock KC, Lee VJ, Citarella RV, Durr FE, Nicolau G, and Kohlbrenner M. N-Phosphoryl derivatives of Bisantrene. Antitumor Prodrugs with Enhanced Solubility and Reduced Potential for Toxicity. J Med Chem 1993; 36:2098–2101PubMedGoogle Scholar
  137. Murphy FJ, Quadagni NP, DeBon F. Use of steroid anesthesia in surgery. JAMA 1955; 158:1412–1414Google Scholar
  138. Murtiashaw MH, Green S, and Stephenson PT. Triazole Derivatives Useful in Therapy. Int Patent WO 9721869, August 7, 1997:33pGoogle Scholar
  139. Mussini E. Marcucci F, Fanelli R, Guaitani A, Garattini S. Analytical and Pharmacokinetic Studies on the Optical Isomers of Oxazepam Succinate Half-Ester. Biochem Pharm 1972; 21:127–129PubMedGoogle Scholar
  140. Nahata M and Powell D. Bioavailability and Clearance of Chloramphenicol After Intravenous Chloramphenicol Succinate. Clin Pharmacol Ther 1981; 30:368–372PubMedCrossRefGoogle Scholar
  141. Nakane M, and Iwana H. A Potential Mechanism of Propofol-Induced Pain on Injection Based on Studies Using Nafamostat Mesilate. Br J Anaesth 1999; 83:397–404PubMedGoogle Scholar
  142. Narisawa S, and Stella VJ. Increased Shelf-life of Fosphenytoin: Solubilization of a Degrant, Phenytoin, through Complexation with (SBE)7m-β-CD. J Pharm Sci 1998; 87:926–930PubMedGoogle Scholar
  143. Newton DW, and Kluza RB. Prediction of Phenytoin Solubility in Intravenous Admixtures: Physicochemical Theory. Am J Hosp Pharm 1980; 37:1647–1651PubMedGoogle Scholar
  144. Nicolaou KC, Riemer C, Kerr MA, Rideout D, and Wrasidlo W. Design, Synthesis and Biological Activity of Protaxols. Nature 1993; 364:464–466PubMedGoogle Scholar
  145. Nicolaou KC, Guy RK, Pitsinos EN, and Wrasidlo W. A Water-Soluble Prodrug of Taxol with Self-Assembling Properties. Angew Chem 1994; 106:1672–1675Google Scholar
  146. Novak E, Wagner JG, and Lamb DJ. Local and Systemic Tolerance, Absorption and Excretion of Clindamycin Hydrochloride after Intramuscular Administration. Int J Clin Pharmacol Ther Toxicol 1970; 3:201–208Google Scholar
  147. Ohwada J, Murasaki C, Yamazaki T, Ichihara S, Umeda I, and Shimma N. Synthesis of Novel Water Soluble Benzylazolium Prodrugs of Lipophilic Azole Antifungals. Bioorg Med Chem Lett 2002; 12:2775–2780PubMedGoogle Scholar
  148. Parker TJ, Daley-Yates PT, and Wood SA. A Comparative Population Pharmacokinetic Analysis for Methylprednisolone Following Multiple Dosing of Two Prodrugs in Patients With Acute Asthma. Br J Clin Pharmacol 1997; 43:589–592PubMedGoogle Scholar
  149. Pendri A, Conover CD, and Greenwald RB. Antitumor Activity of Paclitaxel-2’-glycinate Conjugated to Poly(Ethylene Glycol): A Water-Soluble Prodrug. Anti-Cancer Drug Design 1998; 13:387–395PubMedGoogle Scholar
  150. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ Yu SS, Anderson GD, Burton EG, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, and Isakson PC. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-sulfonamide (SC-58635, Celecoxib). J Med Chem 1997; 40:1347–1365PubMedGoogle Scholar
  151. Pesenti E, Franzetti C, and Ciomei M. Synthesis and biological Activity of Water Soluble Polymer-Bound Taxol Derivatives. Proc Am Ass Cancer Res 1995; 36:307Google Scholar
  152. Pochopin NL, Charman WN, and Stella VJ. Pharmacokinetics of Dapsone and Amino Acid Prodrugs of Dapsone. Drug Metab Dispos 1994; 22:770–775PubMedGoogle Scholar
  153. Pochopin NL, Charman WN, and Stella VJ. Amino Acid Derivatives of Dapsone as Water-Soluble Prodrugs. Int J Pharm 1995; 121:157–167Google Scholar
  154. Pop E, Liu ZZ, Brewster ME, Barenholz Y, Korablyov V, Mechoulam R, Nadler V, and Biegon A. Derivatives of Dexanabinol. I. Water-Soluble Salts of Glycinate Esters. Pharm. Res 1996; 13:62–69PubMedGoogle Scholar
  155. Pop E, Rachwal S, Vlasak J, Biegon A, Zharikova A, Prokai L. In Vitro and In Vivo Study of Water-Soluble Prodrugs of Dexanabinol. J Pharm Sci 1999; 88:1156–1160PubMedGoogle Scholar
  156. Powis G, and Kovach JS. Disposition of Bisantrene in Human and Rabbits: Evidence for Intravascular Deposition of Drug as a Cause of Phlebitis. Cancer Res 1983; 43:925–929PubMedGoogle Scholar
  157. Prankerd RD, and Stella VJ. Use of Oil-in-Water Emulsion as a Vehicle for Parenteral Drug Administration. J Parent Sci Technol 1990; 44:139–149Google Scholar
  158. Prasit P, Wang Z, Brideau C, Chan, CC, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O’Neill GP, Ouellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Tagari P, Therien M, Vickers P, Wong E, Xu LJ, Young RN, Zamboni R, Boyce S, Rupniak N, Forrest M, Visco D, and Patrick D. The Discovery of Rofecoxib, [MK 966, Vioxx, 4-(4′-Methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an Orally Active Cyclooxygenase-2 Inhibitor. Bioorg Med Chem Lett 1999; 9:1773–1778PubMedGoogle Scholar
  159. Prijovich ZM, Chen B-M, Leu Y-L, Chern J-W, and Roffler SR. Antitumor Activity and Toxicity of the New Prodrug 9-Aminocamptothecin Glucuronide (9ACG) in Mice. Br J Cancer 2002; 86:1634–1638PubMedGoogle Scholar
  160. Prijovich ZM, Leu Y-L, and Roffler SR. Stability of the New Prodrug 9-Aminocamptothecin Glucuronide (9ACG) in the Presence of Human Serum Albumin. Biochem Pharmacol 2003; 66:1181–1187PubMedGoogle Scholar
  161. Pryor FM, Gidal B, Ramsay RE, DeToledo J, and Morgan RO, Fosphenytoin: Pharmacokinetics and Tolerance of Intramuscular Loading Doses. Epilepsia 2001; 42:245–250PubMedGoogle Scholar
  162. Ramsay RE, DeToledo JC. Intravenous Administration of Fosphenytoin: Options for the Management of Seizures. Neurology 1996; 46(6 Suppl 1):S17–9PubMedGoogle Scholar
  163. Ramsay RE, Wilder BJ, Uthman BM, Garnett WR, Pellock JM, Barkley GL, Leppik IE, Knapp LE. Intramuscular Fosphenytoin (Cerebyx) in Patients Requiring a Loading Dose of Phenytoin. Epilepsy Res 1997; 28:181–187PubMedGoogle Scholar
  164. Repta AJ, Rawson BJ, Shaffer RD, Sloan KB, Bodor N, and Higuchi T. Rational Development of a Soluble Prodrug of a Cytotoxic Nucleoside: Preparation and Properties of Arabinosyladenine 5′-Formate. J Pharm Sci 1975; 64:392–396PubMedGoogle Scholar
  165. Rohdewald P, Moellmann H, Barth J, Rehder J, and Derendorf H. Pharmacokinetics of Dexamethasone and its Phosphate Ester. Biopharm Drug Dispos 1987; 8:205–212PubMedGoogle Scholar
  166. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, and Jacques C. Randomised Trial of Irinotecan Versus Fluorouracil by Continuous Infusion After Fluorouracil Failure in Patients with Metastatic Colorectal Cancer. Lancet 1998; 352:1407–12PubMedGoogle Scholar
  167. Rowinsky EK, and Donehower RC. The Clinical Pharmacology of Paclitaxel (Taxol). Semin Oncol 1993; 20(4 Suppl 3):16–25PubMedGoogle Scholar
  168. Rowinsky EK, Rizzo J, Ochoa L, Tolchar A, Tachimoto C, Forouzech B, Schwartz G, Hammond LA, Patnaik A, Kwiatek, J, Goetz A, Denis L, McGuire J, and Tolcher, AW. A Phase I and Pharmacokinetic Study of Camptothecin as a 1-hour Infusion Every 3 Weeks in Patients with Advanced Solid Malignancies. J Clin Oncol 2003; 21:148–157PubMedGoogle Scholar
  169. Salmona M, Saronio C, Bianchi R, Marcucci F, and Mussini E. In Vitro Hydrolysis of Oxazepam Succinate Half-Ester by Sterospecific Soluble Esterase from Different Animal Species. J Pharm Sci 1974; 63:222–225PubMedGoogle Scholar
  170. Sanchez-Crespo M. Potential of PAF Receptor Antagonists in the Treatment of Septic Shock. Drug News Perspect 1993; 6:78–87Google Scholar
  171. Sandler A, and van Oosterom AT. Irinotecan in Cancers of the Lung and Cervix. Anti-Cancer Drugs 1999; 10Suppl 1:S13–S17PubMedCrossRefGoogle Scholar
  172. Sawada S, Nokata K, Okajima S, Nagai H, Yaegashi T, Tezuka K, and Miyasaka T. Preparation of 7-ethylcamptothecin (aminoethyl)amide derivatives as antitumor prodrugs. Eur Pat Appl EP 296612 1988; 33pGoogle Scholar
  173. Schacter L. Etoposide Phosphate: What, Why, Where, and How?. Semin Oncol 1996; 23:1–7PubMedGoogle Scholar
  174. Schoettler C, and Krisch K. Hydrolysis of Steroid Hormone Esters by an Unspecific Carboxylesterase from Pig Liver Microsomes. Biochem Pharm 1974; 23:2867–2875Google Scholar
  175. Scott L, Evans T, Yao J, Benson M, Mulcahy A, Decatris T, Falk S, Rudoltz, and Ajani J. Pegamotecan (EZ-246), a novel PEGylated Camptothecin Conjugate, for Treatment of Adenocarcinomas of the Stomach and Gastroesophageal (GE) Junction: Preliminary Results of a Single-Agent Phase-2 Study. ASCO Proceedings, 2004Google Scholar
  176. Schywalsky M, Ihmsen H, Tzabazia A, Fechner J, Burak E, Vornov J, and Schwilden H. Pharmacokinetics and Pharmacodynamics of the New Propofol Prodrug GPI 15715 in Rats. Eur J Anaesthesiol 2003; 20:182–190PubMedGoogle Scholar
  177. Serembe M, and Ospedale C. Hydrolysis of Water-Soluble Esters of Chloramphenicol and Their Antibacterial Activity In Vitro and In Vivo. Minerva Medica 1960; 517–521Google Scholar
  178. Shah JC, Chen JR, and Chow D. Preformulation Study of Etoposide: Identification of Physicochemical Characteristics Responsible for the Low and Erratic Oral Bioavailability of Etoposide. Pharm Res 1989; 6:408–412PubMedGoogle Scholar
  179. Simpson D, and Wagstaff AJ. Estramustine Phosphate Sodium: A Review of its Use in Combination Therapy for Hormone-Refractory Prostate Cancer. Am J Cancer 2003; 2:373–390Google Scholar
  180. Singer JW, de Vries P. Bhatt R. Tulinsky J. Klein P, Li C, Milas L, Lewis RA, and Wallace S. Conjugation of Camptothecin to Poly-(L-glutamic acid). Ann. NY Acad. Sci. 2000; 922:136–150PubMedCrossRefGoogle Scholar
  181. Singer JW, Bhatt R, Tulinsky J, Buhler KR, Heasley E, Klein P, and de Vries P. Water-soluble poly-(L-glutamic acid)-Gly-camptothecin Conjugates Enhance Camptothecin Stability and Efficacy In Vivo. J Control Release 2001; 74:243–247PubMedGoogle Scholar
  182. Singer J, Baker B, de Vries P, Kumar A, Shaffer S, Vawter E, Bolton M, and Barzone P. Poly-(L)-Glutamic Acid-Paclitaxel (CT-2103) [XYOTAX®], a Biodegradable Polymeric Drug Conjugate. Characterization, Preclinical Pharmacology, and Preliminary Clinical Data. In: Maeda H, Kabanov A, Kataoka K and Okano T. Polymer Drugs in the Clinical Stage Advantages and Prospects New York, NY: Kluwer Academic/Plenum Publishers 2003; 81–99Google Scholar
  183. Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DS, Pesheck CV, and Lord RS. Pharmacokinetics, Metabolism, and Excretion of Irinotecan (CPT-11) Following I.V. Infusion of [14C]CPT-11 in Cancer Patients. Drug Metab Dispos 2000; 28:423–433PubMedGoogle Scholar
  184. Slevin ML. The Clinical Pharmacology of Etoposide. Cancer 1991; 67:319–329PubMedGoogle Scholar
  185. Sobue S, Sekiguchi K, Shimatani K, and Tan K. Pharmacokinetics and Safety of Fosfluconazole after Single Intravenous Bolus Injection in Healthy Male Japanese Volunteers. J Clin Pharmacol 2004; 44:284–292PubMedGoogle Scholar
  186. Spengler RF, Arrowsmith JB, Kilarski DJ, Buchanan C, Von Behren L, Graham DR. Severe Soft-Tissue Injury Following Intravenous Infusion of Phenytoin. Patient and Drug Administration Risk Factors. Arch Intern Med 1988; 148:1329–1333PubMedGoogle Scholar
  187. Stella VJ. A Case for Prodrugs: Fosphenytoin. Adv Drug Deliv Rev 1996; 19:311–330Google Scholar
  188. Stella VJ, and Kennedy PE. Prodrugs of Rapamycin. US Patent 4,650,803. Mar. 17, 1987; 6pGoogle Scholar
  189. Stella VJ, Zygmunt JJ, Georg IG, and Safadi, MS. Water-Soluble Prodrugs of Hindered Alcohols or Phenols. PCT Int Appl WO 2000008033 Feb. 17, 2000; 76pGoogle Scholar
  190. Sugahara SI, Kajiki M, Kuriyama H, and Kobayashi Tr. Paclitaxel Delivery Systems: The Use of Amino Acid Linkers in the Conjugation of Paclitaxel with Carboxymethyldextran to Create Prodrugs. Biol Pharm Bull 2002; 25:632–641PubMedGoogle Scholar
  191. Summers JB, Albert DH, Davidsen SK, Conway RG, Holms JH, Magoc TJ, Luo G, Tapang P, and Rhein DA. ABT-299, a potent antagonist of platelet activating factor. Prostaglandin Thromboxane Leukot Res 1995; 23:475–477Google Scholar
  192. Supko JG, and Malspeis L. Dose-Dependent Pharmacokinetics of Rapamycin-28-N,N-Dimethylglycinate in the Mouse. Cancer Chemother Pharmacol 1994; 33:325–330PubMedGoogle Scholar
  193. Takata J, Karube Y, Hanada M, Matsunaga K, Matsushima Y, Sendo T, and Toshinobu A. Vitamin K prodrugs: 1. Synthesis of Amino Acid Esters of Menahydroquinone-4 and Enzymatic Reconversion to an Active Form. Pharm Res 1995a; 12:18–23PubMedGoogle Scholar
  194. Takata J, Karube Y, Hanada M, Matsunaga K, Matsushima Y, Sendo T, and Oishi R. Vitamin K Prodrugs: 2. Water-soluble Prodrugs of Menahydroquinone-4 for Systemic Site-Specific Delivery. Pharm Res 1995b; 12:1973–1979PubMedGoogle Scholar
  195. Takata J, Karube Y, Matsunaga K, Hanada M, Hidaka R, and Matsushima Y. Prodrugs for Systemic Bioreductive Activation-Independent Delivery of Phyllohydroquinone, An Active Form of Phylloquinone (Vitamin K1). 1: Preparation and In Vitro Evaluation. Biol Pharm Bull 1999; 22:1347–1354PubMedGoogle Scholar
  196. Tally FP, and Sullivan CE. Metronidazole: In Vitro Activity, Pharmacology and Efficacy in Anaerobic Bacterial Infections. Pharmacotherapy 1981; 1:28–38PubMedGoogle Scholar
  197. Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS, Koboldt CM, Yuan J, Zhang YY, Seibert K. N-[[(5-Methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, Sodium Salt, Parecoxib Sodium: A Potent and Selective Inhibitor of COX-2 for Parenteral Administration. J Med Chem 2000; 43:1661–1663PubMedGoogle Scholar
  198. Terwogt JMM, Huinink WWB, Schellens JHM, Schot M, Mandjes IAM, Zurlo MG, Rocchetti M, Rosing H, Koopman FJ, and Beijnen JH. Phase I Clinical and Pharmacokinetic Study of PNU166945, a Novel Water-Soluble Polymer-Conjugated Prodrug of Paclitaxel. Anticancer Drugs 2001; 12:315–323Google Scholar
  199. Trivellato E, Malesani L, and Concilio C. Some New Esters of Chloramphenicol. IV. Pharmacological Research on Chloramphenicol Glycinate. Farmaco, ed sc, Pavia 1958; 13:399–405Google Scholar
  200. Ueda Y, Mikkilineni AB, Knipe JO, Rose WC, Casazza AM, and Vyas DM. Novel Water Soluble Phosphate Prodrugs of Taxol Possessing In Vivo Antitumor Activity. Bioorg Med Chem Lett 1993; 3:1761–1766Google Scholar
  201. Ueda Y, Matiskella JD, Golik J, Connolly TP, Hudyma TW, Ventaesh S, Dali M, Kang S-H, Barbour N, Tejwani R, Varia S, Knipe J, Zheng M, Mathew M, Mosure K, Clark J, Lamb L, Medin I, Gao Q, Huang S, Chen C-P, and Bronson JJ. Phosphonooxymethyl Prodrugs of the Broad Spectrum Antifungal Azole, Ravuconazole: Synthesis and Biological Properties. Bioorg Med Chem Lett 2003; 13:3669–3672PubMedGoogle Scholar
  202. Uthman BM, Wilder BJ, Ramsay RE. Intramuscular Use of Fosphenytoin: An Overview. Neurology 1996:46(Suppl. 1):S24–S28PubMedGoogle Scholar
  203. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, and Rustum YM. Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview. J Clin Oncol 2001; 19:1501–1518PubMedGoogle Scholar
  204. Varia SA, Schuller S, Sloan KB, and Stella V J. Phenytoin prodrugs. III: Water-Soluble Prodrugs for Oral and/or Parenteral Use. J Pharm Sci 1984a; 1068–1073Google Scholar
  205. Varia SA, Schuller S, and Stella V J. Phenytoin prodrugs. IV: Hydrolysis of Various 3-(Hydroxymethyl)phenytoin Esters. J Pharm Sci 1984b; 1074–1080Google Scholar
  206. Varia SA, and Stella VJ. Phenytoin Prodrugs. V: In Vivo Evaluation of Some Water-Soluble Phenytoin Prodrugs in Dogs. J Pharm Sci 1984a; 1080–1087Google Scholar
  207. Varia SA. and Stella VJ. Phenytoin prodrugs. VI: In Vivo Evaluation of a Phosphate Ester Prodrug of Phenytoin After Parenteral Administration to Rats. J Pharm Sci 1984b; 1087–1090Google Scholar
  208. Vishnvvajjala R, and Garzon-Aburbey A. Preparation of Water-Soluble Derivatives of Camptothecin and their Use as Prodrugs in Cancer Therapy. US Pat Appl US 104894 1990; 21pGoogle Scholar
  209. Vyas DM, Wong H, Crosswell AR, Casazza AM, Knipe JO, Mamber SW, and Doyle TW. Synthesis and Antitumor Evaluation of Water Soluble Taxol Phosphates. Bioorg Med Chem Lett 1993; 3:1357–1360Google Scholar
  210. Vyas DM, Ueda Y, Wong H, Matiskella, JD, Hauck S, Mikkilineni AB, Farina V, Rose WC, and Casazza AM. Phosphatase-Activated Prodrugs of Paclitaxel. ACS Symposium Series 1995; 583:124–137CrossRefGoogle Scholar
  211. Walkenstein SS, Wiser R, Gudmundsen CH, Kimmel HB, Corradino RA. Absorption, Metabolism, and Excretion of Oxazepam and its Succinate Half-Ester. 1964; 53:1181–1186Google Scholar
  212. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, and Sim GA. Plant antitumor agents I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca Acuminata. J Am Chem Soc 1966; 88:3888–3890Google Scholar
  213. Wall ME, and Wani MC. Antineoplastic Agents from Plants. Annu Rev Pharmacol Toxicol 1977; 17:117–132PubMedGoogle Scholar
  214. Wang SM, Chern JW, Yeh MY, Tung E, and Roffler SR. Specific Activation of Glucuronide Prodrugs by Antibody-Targeted Enzyme Conjugates for Cancer Therapy. Cancer Res. 1992; 52:4484–4491PubMedGoogle Scholar
  215. Wani MC, Ronman PE, Lindley JT, and Wall ME. Plant Antitumor Agents. 18. Synthesis and Biological Activity of Camptothecin Analogues. J Med Chem 1980; 23:554–560PubMedGoogle Scholar
  216. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR, Van Echo DA, Von Hoff DD, and Leyland-Jones B. Hypersensitivity Reactions From Taxol. Am J Clin Oncol 1990; 8:1263–1268Google Scholar
  217. Wrasidlo W, Gaedicke G, Guy RK, Renaud J, Pitsinos E, Nicolaou KC, Reisfeld RA, and Lode HN. A Novel 2’-(N-Methylpyridinium Acetate) Prodrug of Paclitaxel Induces Superior Antitumor Responses in Preclinical Cancer Models. Bioconjug Chem 2002; 13:1093–1099PubMedGoogle Scholar
  218. Yalkowsky SH, Krzyzaniak JK, and Ward GH. Formulation-Related Problems Associated with Intravenous Drug Delivery. J Pharm Sci 1998; 87:787–796PubMedGoogle Scholar
  219. Zhao Z, Kingston DGI, and Crosswell AR. Modified Taxols, 6. Preparation of Water-Soluble Prodrugs of Taxol. J Nat Prod 1991; 54:1607–1611Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Jeffery Hemenway
    • 1
  • Valentino J. Stella
    • 2
  1. 1.Bristol-Myers SquibbNew BrunswickUSA
  2. 2.Department of Pharmaceutical ChemistryThe University of KansasLawrenceUSA

Personalised recommendations